This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701. doi: 10.1097/01. sla.0000257358.56863.cePeetersKCMarijnenCANagtegaalIDKranenbargEKPutterHWiggersTThe TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinomaAnn Surg200724669370110.1097/01.sla.0000257358.56863.ce17968156Open DOISearch in Google Scholar
Gollins S, Sebag-Montefiore D. Neoadjuvant treatment strategies for locally advanced rectal cancer. Clin Oncol 2016; 28: 146-51. doi: 10.1016/j. clon.2015.11.003GollinsSSebag-MontefioreDNeoadjuvant treatment strategies for locally advanced rectal cancerClin Oncol2016281465110.1016/j.clon.2015.11.00326645661Open DOISearch in Google Scholar
De Felice F, Benevento I, Magnante AL, Musio D, Bulzonetti N, Caiazzo R, et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A meta-analysis. BMC Cancer 2017; 17: 1-6. doi: 10.1186/s12885-017-3323-4De FeliceFBeneventoIMagnanteALMusioDBulzonettiNCaiazzoRClinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A meta-analysisBMC Cancer2017171610.1186/s12885-017-3323-4542762328499428Open DOISearch in Google Scholar
Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-74. doi: 10.1200/JCO.2005.04.4875ChauIBrownGCunninghamDTaitDWotherspoonANormanARNeoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerJ Clin Oncol2006246687410.1200/JCO.2005.04.487516446339Open DOISearch in Google Scholar
Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont MJ, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined. J Clin Oncol 2010; 28: 859-65. doi: 10.1200/JCO.2009.25.8541Fernández-MartosCPericayCAparicioJSaludASafontMJMassutiBPhase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-definedJ Clin Oncol2010288596510.1200/JCO.2009.25.854120065174Open DOISearch in Google Scholar
Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018; 4: e180071. doi: 10.1001/jamaoncol.2018.0071CercekARoxburghCSDStrombomPSmithJJTempleLKFNashGMAdoption of total neoadjuvant therapy for locally advanced rectal cancerJAMA Oncol20184e18007110.1001/jamaoncol.2018.0071588516529566109Open DOISearch in Google Scholar
Benson AB 3rd, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. NCCN clinical practice guidelines in oncology rectal cancer Version 1.2019 2019. [cited 2019 Apr 25]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdfBensonABVenookAPAl-HawaryMMArainMAChenYJCiomborKKNCCN clinical practice guidelines in oncology rectal cancer Version 1.20192019[cited 2019 Apr 25]. Available athttps://www.nccn.org/professionals/physician_gls/pdf/rectal.pdfSearch in Google Scholar
Bujko K, Bujko M. Point: Short-course radiation therapy is preferable in the neoadjuvant treatment of rectal cancer. Semin Radiat Oncol 2011; 21: 220-7. doi: 10.1016/j.semradonc.2011.02.008BujkoKBujkoMPoint: Short-course radiation therapy is preferable in the neoadjuvant treatment of rectal cancerSemin Radiat Oncol201121220710.1016/j.semradonc.2011.02.00821645867Open DOISearch in Google Scholar
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv263. doi: 10.1093/annonc/mdy161Glynne-JonesRWyrwiczLTiretEBrownGRödelCCervantesARectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201829Suppl 4iv26310.1093/annonc/mdy16129741565Open DOISearch in Google Scholar
But-Hadzic J, Anderluh F, Brecelj E, Edhemovic I, Secerov-Ermenc A, Hudej R, et al. Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost: a Phase 2 Trial. Int J Radiat Oncol Biol Phys 2016; 96: 1003-10. doi: 10.1016/j.ijrobp.2016.08.031But-HadzicJAnderluhFBreceljEEdhemovicISecerov-ErmencAHudejRAcute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost: a Phase 2 TrialInt J Radiat Oncol Biol Phys20169610031010.1016/j.ijrobp.2016.08.03127727065Open DOISearch in Google Scholar
Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 2009. [cited 2019 Apr 25]. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfCancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 2009. [cited 2019 Apr 25]http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfSearch in Google Scholar
Edge SB, Compton CC. The american joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4. doi: 10.1245/s10434-010-0985-4EdgeSBComptonCCThe american joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol2010171471410.1245/s10434-010-0985-420180029Open DOISearch in Google Scholar
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23. PMID: 9112145DworakOKeilholzLHoffmannAPathological features of rectal cancer after preoperative radiochemotherapyInt J Colorectal Dis1997121923PMID: 911214510.1007/s0038400500729112145Search in Google Scholar
IBM Corp. Released 2018. IBM SPSS Statistics for Windows, Version 26.0 Armonk: IBM Corp; 2018.IBM Corp. Released2018IBM SPSS Statistics for Windows, Version 26.0ArmonkIBM Corp2018Search in Google Scholar
Golo D, But-Hadzic J, Anderluh F, Brecelj E, Edhemovic I, Jeromen A, et al. Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - Long-term results of phase II OIGIT-01 Trial. Radiol Oncol 2018; 52: 267-74. doi: 10.2478/raon-2018-0028GoloDBut-HadzicJAnderluhFBreceljEEdhemovicIJeromenAInduction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - Long-term results of phase II OIGIT-01 TrialRadiol Oncol2018522677410.2478/raon-2018-0028613735430210040Open DOISearch in Google Scholar
Wang X, Yu Y, Meng W, Jiang D, Deng X, Wu B, et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. Radiother Oncol 2018; 129: 300-5. doi: 10.1016/j.radonc.2018.08.027WangXYuYMengWJiangDDengXWuBTotal neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trialRadiother Oncol2018129300510.1016/j.radonc.2018.08.02730381141Open DOISearch in Google Scholar
Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30: 1620-7. doi:10.1200/JCO.2011.39.6036DewdneyACunninghamDTaberneroJCapdevilaJGlimeliusBCervantesAMulticenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)J Clin Oncol2012301620710.1200/JCO.2011.39.603622473163Open DOISearch in Google Scholar
But-Hadzic J, Velenik V. Preoperative intensity-modulated chemoradiation therapy with simultaneous integrated boost in rectal cancer: 2-year follow-up results of phase II study. Radiol Oncol 2018; 52: 23-9. doi: 10.1515/raon-2018-0007But-HadzicJVelenikVPreoperative intensity-modulated chemoradiation therapy with simultaneous integrated boost in rectal cancer: 2-year follow-up results of phase II studyRadiol Oncol20185223910.1515/raon-2018-0007583907829520202Open DOISearch in Google Scholar
Kalady MF, De Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009; 250: 582-8. doi: 10.1097/SLA.0b013e3181b91e63KaladyMFDe Campos-LobatoLFStocchiLGeislerDPDietzDLaveryICPredictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancerAnn Surg2009250582810.1097/SLA.0b013e3181b91e6319710605Open DOISearch in Google Scholar
Francois BY, Nemoz CJ, Baulieux J, Vignal J, Grandjean J, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396-402. doi: 10.1200/JCO.1999.17.8.2396FrancoisBYNemozCJBaulieuxJVignalJGrandjeanJPartenskyCInfluence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trialJ Clin Oncol199917239640210.1200/JCO.1999.17.8.239610561302Open DOISearch in Google Scholar
Goodman KA. Total neoadjuvant therapy for rectal cancer. Cancer Radiother 2018; 22: 459-65. doi: 10.1016/j.canrad.2018.01.004GoodmanKATotal neoadjuvant therapy for rectal cancerCancer Radiother2018224596510.1016/j.canrad.2018.01.00429807808Open DOISearch in Google Scholar
George TJ, Allegra CJ, Yothers G. Neoadjuvant rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trials. Curr Colorectal Cancer Rep 2015; 11: 275-80. doi: 10.1007/s11888-015-0285-2GeorgeTJAllegraCJYothersGNeoadjuvant rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trialsCurr Colorectal Cancer Rep2015112758010.1007/s11888-015-0285-2455064426321890Open DOISearch in Google Scholar
Yothers G, George TJ, Allegra CJ, Bosset J-F, Bujko K, Collette L, et al. Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. [Abstract]. J Clin Oncol 2016; 34(15 Suppl): 3533. doi: 10.1200/JCO.2016.34.15_suppl.3533YothersGGeorgeTJAllegraCJBossetJ-FBujkoKColletteLPredictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. [Abstract]J Clin Oncol20163415 Suppl353310.1200/JCO.2016.34.15_suppl.3533Open DOISearch in Google Scholar
Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius B, et al. Short- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C Trial. Int J Radiat Oncol 2015; 93: 303-12. doi: 10.1016/j.ijrobp.2015.03.038SclafaniFPeckittCCunninghamDTaitDGiraltJGlimeliusBShort- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C TrialInt J Radiat Oncol2015933031210.1016/j.ijrobp.2015.03.038Open DOISearch in Google Scholar
Schou J V., Larsen FO, Rasch L, Linnemann D, Langhoff J, Høgdall E, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 2012; 23: 2627-33. doi: 10.1093/annonc/mds056SchouJ V.LarsenFORaschLLinnemannDLanghoffJHøgdallEInduction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancerAnn Oncol20122326273310.1093/annonc/mds056Open DOISearch in Google Scholar
Zaborowski A, Stakelum A, Winter DC. Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer. BJS 2019; 106: 979-87. doi: 10.1002/bjs.11171ZaborowskiAStakelumAWinterDCSystematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancerBJS20191069798710.1002/bjs.11171Open DOISearch in Google Scholar
Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15: 184-90. doi: 10.1016/S1470-2045(13)70599-0BossetJFCalaisGMineurLMaingonPStojanovic-RundicSBensadounRJFluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised studyLancet Oncol2014151849010.1016/S1470-2045(13)70599-0Open DOISearch in Google Scholar
Herrle F, Sandra-Petrescu F, Weiss C, Post S, Runkel N, Kienle P. Quality of life and timing of stoma closure in patients with rectal cancer undergoing low anterior resection with diverting stoma: A multicenter longitudinal observational study. Dis Colon Rectum 2016; 59: 281-90. doi: 10.1097/DCR.0000000000000545HerrleFSandra-PetrescuFWeissCPostSRunkelNKienlePQuality of life and timing of stoma closure in patients with rectal cancer undergoing low anterior resection with diverting stoma: A multicenter longitudinal observational studyDis Colon Rectum2016592819010.1097/DCR.000000000000054526953986Open DOISearch in Google Scholar
